Literature DB >> 821579

Determination of the in vitro sensitivity of Brucella strains to rifampicin.

M J Corbel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 821579     DOI： 10.1016/s0007-1935(17)34686-9

Source DB:  PubMed          Journal:  Br Vet J        ISSN： 0007-1935


× No keyword cloud information.
  7 in total

1.  Determination of stability of Brucella abortus RB51 by use of genomic fingerprint, oxidative metabolism, and colonial morphology and differentiation of strain RB51 from B. abortus isolates from bison and elk.

Authors:  A E Jensen; D R Ewalt; N F Cheville; C O Thoen; J B Payeur
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

2.  Possible implications of doxycycline-rifampin interaction for treatment of brucellosis.

Authors:  J D Colmenero; L C Fernández-Gallardo; J A Agúndez; J Sedeño; J Benítez; E Valverde
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

3.  In vitro activity of N-formimidoyl thienamycin against 98 clinical isolates of Brucella melitensis compared with those of cefoxitin, rifampin, tetracycline, and co-trimoxazole.

Authors:  A Gutiérrez Altés; M Díez Enciso; P Peña García; A Campos Bueno
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

4.  Relevance of in vitro antimicrobial susceptibility of Brucella melitensis to relapse rate in human brucellosis.

Authors:  J Ariza; J Bosch; F Gudiol; J Liñares; P F Viladrich; R Martín
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

5.  Doxycycline-rifampin versus doxycycline-streptomycin in treatment of human brucellosis due to Brucella melitensis. The GECMEI Group. Grupo de Estudio de Castilla-la Mancha de Enfermedades Infecciosas.

Authors:  J Solera; M Rodríguez-Zapata; P Geijo; J Largo; J Paulino; L Sáez; E Martínez-Alfaro; L Sánchez; M A Sepulveda; M D Ruiz-Ribó
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

6.  In vitro susceptibility of Brucella melitensis to new cephalosporins crossing the blood-brain barrier.

Authors:  E Palenque; J R Otero; A R Noriega
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

7.  Comparative trial of rifampin-doxycycline versus tetracycline-streptomycin in the therapy of human brucellosis.

Authors:  J Ariza; F Gudiol; R Pallarés; G Rufí; P Fernández-Viladrich
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.